These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 27592869)

  • 21. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
    Sawada H; Kanehisa F; Katoh N; Asai J
    J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
    Mizukami Y; Kanemaru H; Nakamura K; Hashigo S; Kajihara I; Miyashita A; Aoi J; Fukushima S; Honda Y; Ihn H
    J Dermatol; 2020 Apr; 47(4):e126-e127. PubMed ID: 31872454
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
    Seghers AC; Wilgenhof S; Lebbé C; Neyns B
    Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
    Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
    Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
    Melin A; Routier E; Tissot H; Rouleau E; Robert C
    Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
    [No Abstract]   [Full Text] [Related]  

  • 27. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
    Schreuer M; Meersseman G; Van Den Herrewegen S; Jansen Y; Chevolet I; Bott A; Wilgenhof S; Seremet T; Jacobs B; Buyl R; Maertens G; Neyns B
    J Transl Med; 2016 Apr; 14():95. PubMed ID: 27095081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to BRAF-targeted therapy in melanoma.
    Sullivan RJ; Flaherty KT
    Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
    Ibrahim T; Routier E; Weill A; Baz M; Robert C
    Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].
    Kopecký J; Kubeček O
    Klin Onkol; 2016; 29(2):133-8. PubMed ID: 27081804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.
    Kiyohara T; Nagano N; Miyamoto M; Shijimaya T; Nakamaru S; Makimura K; Tanimura H
    Clin Exp Dermatol; 2019 Dec; 44(8):945-946. PubMed ID: 30950075
    [No Abstract]   [Full Text] [Related]  

  • 34. The future of melanoma therapy: developing new drugs and improving the use of old ones.
    Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
    Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
    [No Abstract]   [Full Text] [Related]  

  • 35. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 36. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
    Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G
    Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
    Akabane H; Sullivan RJ
    Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.